Autolus Therapeutics Plc (AUTL)
1.50
-0.31
(-17.13%)
USD |
NASDAQ |
Jan 12, 16:00
1.49
-0.01
(-0.67%)
After-Hours: 20:00
Autolus Therapeutics Research and Development Expense (Quarterly): 27.72M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Biodexa Pharmaceuticals Plc | -- |
| NuCana Plc | 2.928M |
| Mereo BioPharma Group Plc | 4.244M |
| Bicycle Therapeutics Plc | 65.65M |
| Adaptimmune Therapeutics Plc | 25.95M |